The rising tide of trial transparency
This article was originally published in Scrip
Executive Summary
The tide seems to be turning in the clinical trial disclosure debate, and not in the industry's favor. True, the "principles for responsible data sharing" drawn up last year by industry bodies EFPIA and PhRMA came into effect on 1 January, and several companies, now including Sanofi, have accordingly announced policies in line with those principles.